NovImmune: Sobi acquires global rights for emapalumab from Novimmune
Following approvals from relevant competition authorities, Swedish Orphan Biovitrum AB (Sobi) has completed the acquisition of the perpetual global rights to emapalumab from Novimmune SA. That Sobi
Read full article »
NovImmune discovers and develops antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer.
Read more